Remove Clinical Research Remove Nurses Remove Radiology Remove Trials
article thumbnail

Why I Fight | A message from Gary Fishbein, MD, MPH

Worldwide Clinical Trials

Join us as we celebrate cancer research awareness month and clinical trials awareness month. Where I trained at the University of Maryland, there was literally a bridge that connected the research labs to the clinic. Life after cancer is about more than just survival. Building Bridges. Every Patient Is Precious.

article thumbnail

Key Items Auditors Look for When Reviewing an Investigator Site File

Advarra

Maintaining complete and compliant documentation while managing the complex processes and interactions of clinical trial conduct is complicated. Investigator Site Files The ISF contains essential documents permitting evaluation of a clinical trial’s conduct. associates, residents, research fellows). based sites.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Maximizing Study Start-up Efficiency – 8 Tips for Streamlining the Coverage Analysis Process

WCG Clinical

With many clinical research sites facing study start-up delays and backlogs, performing a coverage analysis efficiently and thoroughly is critical to the study start-up process. But why is the coverage analysis process so vital for clinical trials and how can research sites do it more effectively?

article thumbnail

Considerations for Neuroscience Trials with Intrathecal Delivery and Other Methods of Direct CNS Administration

XTalks

Clinical research experts from the CRO Medpace shared insights about the operational and regulatory considerations for neuroscience trials with direct CNS administration. In a recent webinar, Dr. Vornov described the history and current progress in targeted CNS therapeutic delivery.

Trials 83
article thumbnail

COVID-19 Pandemic Coverage

XTalks

By the end of August, the World Health Organization (WHO) counted 33 vaccine candidates in some stage of clinical trial evaluation. As of July, the company and its federal partner stated that it is on track to supply between 500 million to 1 billion doses a year at a dose of 100 µg now selected for their Phase III trial.